Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Schulman

Showing results (161-170 of 308) with videos related to

Pageof 31
Sort By:
BMJ (Clinical Research Ed.)|May 26, 2011
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsFlorent Boutitie, Laurent Pinede, Sam Schulman, et al.
Thrombosis and Haemostasis|August 23, 2024
Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein ThrombosisKatarina Glise Sandblad, Carl Johan Svensson, Kristina Svennerholm, et al.
BMJ Open|October 31, 2023
TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocolIlia Makedonov, Susan Kahn, Jameel Abdulrehman, et al.
European Journal of Internal Medicine|March 20, 2026
Long-term mortality in patients with first-time pulmonary embolism according to the presence of comorbidities at baseline: a nationwide register studyMazdak Tavoly, Kristina Svennerholm, Jacob Philipson, et al.
Pilot and Feasibility Studies|April 30, 2020
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndromeKimberly Legault, Mark Blostein, Marc Carrier, et al.
Thrombosis and Haemostasis|July 15, 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER IISamuel Z Goldhaber, Sebastian Schellong, Ajay Kakkar, et al.
BMJ Open|September 14, 2021
MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trialJean Philippe Galanaud, Jameel Abdulrehman, A Lazo-Langner, et al.
British Journal of Haematology|March 4, 2006
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolismKarin Wåhlander, Henry Eriksson, Torbjörn Lundström, et al.
Chest|April 3, 2013
Response to Dr JunqueiraLori-Ann Linkins, Antonio L Dans, Col Lisa K Moores, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2021
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patientsHilde Skuterud Wik, Susan R Kahn, Henry Eriksson, et al.
Pageof 31

Showing results (161-170 of 308) with videos related to

Sort By:
Pageof 31
BMJ (Clinical Research Ed.)|May 26, 2011
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsFlorent Boutitie, Laurent Pinede, Sam Schulman, et al.
Thrombosis and Haemostasis|August 23, 2024
Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein ThrombosisKatarina Glise Sandblad, Carl Johan Svensson, Kristina Svennerholm, et al.
BMJ Open|October 31, 2023
TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocolIlia Makedonov, Susan Kahn, Jameel Abdulrehman, et al.
European Journal of Internal Medicine|March 20, 2026
Long-term mortality in patients with first-time pulmonary embolism according to the presence of comorbidities at baseline: a nationwide register studyMazdak Tavoly, Kristina Svennerholm, Jacob Philipson, et al.
Pilot and Feasibility Studies|April 30, 2020
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndromeKimberly Legault, Mark Blostein, Marc Carrier, et al.
Thrombosis and Haemostasis|July 15, 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER IISamuel Z Goldhaber, Sebastian Schellong, Ajay Kakkar, et al.
BMJ Open|September 14, 2021
MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trialJean Philippe Galanaud, Jameel Abdulrehman, A Lazo-Langner, et al.
British Journal of Haematology|March 4, 2006
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolismKarin Wåhlander, Henry Eriksson, Torbjörn Lundström, et al.
Chest|April 3, 2013
Response to Dr JunqueiraLori-Ann Linkins, Antonio L Dans, Col Lisa K Moores, et al.
Journal of Thrombosis and Haemostasis : JTH|July 13, 2021
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patientsHilde Skuterud Wik, Susan R Kahn, Henry Eriksson, et al.
Pageof 31